CHU de Reims

chu-reims.fr

Total trials

273

Active

46

Phase 3

9

Total enrollment

71,283

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 11 of 11 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space1
Injection of Isotonic saline + 2 mg morphine into the epidural space1
PCR multiplex by FilmArray1
Triamcinolone Acetonide1
saline solution1
Blood sampling1
Liquid bubble sampling1
Blood sampling & Chest CT without1
blood test1
microbiology1
histology1

Next readouts

  • 2025-01-10
  • 2026-11
  • 2027-01-07
  • 2027-01-11
  • 2027-07
  • 2028-06

Top conditions

  • Bullous Pemphigoid6
  • Alzheimer Disease4
  • Pregnancy4
  • Bipolar Disorder4
  • Obesity4
  • Hidradenitis Suppurativa3
  • Periodontitis3
  • Gingivitis3

Frequently asked questions about CHU de Reims

How many clinical trials does CHU de Reims have on ClinicalTrials.gov?
CHU de Reims is listed as the lead sponsor on 273 clinical trials in ClinicalTrials.gov, 46 of which are currently active (recruiting, enrolling, or ongoing).
How many of CHU de Reims's trials are in Phase 3?
9 of CHU de Reims's trials are in Phase 3, spread across 11 active drug programs.
What therapeutic areas does CHU de Reims focus on?
CHU de Reims's most-studied conditions on ClinicalTrials.gov are Bullous Pemphigoid, Alzheimer Disease, Pregnancy, Bipolar Disorder, Obesity.
When are CHU de Reims's next clinical trial readouts?
CHU de Reims has 6 upcoming primary-completion readouts tracked here; the soonest is “Deciphering IL-17-dependant Inflammatory Response in Bullous Pemphigoid”, expected around 2025-01-10.